CryoEM structure of amplified alpha-synuclein fibril class A type I with extended core from DLB case VII
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
CryoEM structure of amplified alpha-synuclein fibril class A type I with extended core from DLB case X
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
CryoEM structures of amplified alpha-synuclein fibril class B type II with extended core from DLB case I
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli BL21(DE3) Mutation(s): No
CryoEM structures of amplified alpha-synuclein fibril class B mixed type I/II with extended core from DLB case II
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
CryoEM structures of amplified alpha-synuclein fibril class B type I with compact core from DLB case III
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
CryoEM structure of amplified alpha-synuclein fibril class B type I with extended core from DLB case VII
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
CryoEM structure of amplified alpha-synuclein fibril class B type II with extended core from DLB case VII
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
CryoEM structure of amplified alpha-synuclein fibril class B type I with extended core from DLB case X
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
Alpha-synuclein fibril from spontaneous control
By Emma Sherrell onClassification: PROTEIN FIBRIL Organism(s): Homo sapiens Expression System: Escherichia coli 'BL21-Gold(DE3)pLysS AG Mutation(s): No
Boles_et-al_DSS_time-series
By Emma Sherrell onProcessed and normalized counts after the removal of low-quality genes and samples. These data are separated into colon ("colon_clean_VST_counts.csv") and brain ("brain_clean_VST_counts.csv"). The sample key can be found in the metadata at the GEO entry page. This repository contains the code that was used to generate these cleaned counts from the raw counts.
Examining the brain’s response to intestinal permeability and inflammation in the dextran sulfate sodium-induced colitis model
By Emma Sherrell onFrom the brain, cortex, hippocampus, ventral midbrain, and striatum were taken to examine both global and regionally-specific transcriptomic perturbances that emerge in response to gut leakiness. All tissues were assayed with high-throughput RNA sequencing.
Gut mucosal cells transfer α-synuclein to the vagus nerve
By Emma Sherrell onPublished: These findings highlight a potential non-neuronal source of fibrillar α-synuclein protein that might arise in gut mucosal cells. View original preprint.
DAB antibody (IHC) staining protocol
By Emma Sherrell onThis is the basic protocol for antibody staining of formalin fixed paraffin embedded (FFPE) tissue. This is the basic protocol for antibody staining of formalin fixed paraffin embedded (FFPE) tissue.
Comparative analysis of methods to reduce activation signature gene expression in PBMCs
By Julia Julia Leonard onPreprint: These findings highlight the importance of considering the advantages and drawbacks of different isolation methods to ensure accurate interpretation of PBMC transcriptomic profiles.
VPS13B is localized at the cis-trans Golgi complex interface and is a functional partner of FAM177A1
By Julia Julia Leonard onPreprint: These findings raise the possibility that bulk lipid transport by VPS13B may play a role in expanding Golgi membranes and that VPS13B may be assisted in this function by FAM177A1.
A STING-CASM-GABARAP pathway activates LRRK2 at lysosomes
By Julia Julia Leonard onPreprint: These results define a pathway that integrates multiple stimuli at lysosomes to control the kinase activity of LRRK2. Aberrant activation this pathway may be of relevance in both Parkinson’s and Crohn’s diseases.
Lysosomal TBK1 responds to amino acid availability to relieve Rab7-Dependent mTORC1 inhibition
By Julia Julia Leonard onPreprint: Data establishes the lysosome as a site of amino acid regulated TBK1 signaling that is crucial for efficient mTORC1 activation. This lysosomal pool of TBK1 has broader implications for lysosome homeostasis, and its dysregulation could contribute to the pathogenesis of ALS-FTD.
